1-3 of 3
Honghu Zhu, PhD
Close
Sort by
Journal Articles

Risk-Stratification Treatment Directed by Minimal Residual Disease Improves the Outcome of Acute Myeloid Leukemia with t(8;21) in First Complete Remission: Results of the AML05 Multicentre Trial

Honghu Zhu, PhD, Xiao-hui Zhang, MD, PhD, Yazhen Qin, Hao Jiang, MD, Dai-Hong Liu, MD, PhD, Huan Chen, Qian Jiang, MD, Jun-Yue Chai, Li-Ru Wang, Xiaojun Huang
Journal: Blood
Blood (2012) 120 (21): 139.
https://doi.org/10.1182/blood.V120.21.139.139
Published: 2012
Journal Articles

CD58-Negtive Leukemia Initiating Cells Are Independently Associated with High Risk of Relapse in B-Precursor Acute Lymphoblastic Leukemia: A Comprehensive Clinical and Biological Profiling Study

Yuan Kong, MD, PhD, Yanrong Liu, MD, Honghu Zhu, PhD, Qian Jiang, MD, Hao Jiang, MD, Lan-Ping Xu, MD, Dai-Hong Liu, MD, PhD, Guo-Rui Ruan, PhD, Bin Jiang, MD, Kaiyan Liu, MD, Xiao-jun Huang, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 1397.
https://doi.org/10.1182/blood.V120.21.1397.1397
Published: 2012
Journal Articles

The PRAME and WT1 Transcripts Constitute a Good Molecular Marker Combination for Monitoring Minimal Residual Disease in Myelodysplastic Syndromes

Yazhen Qin, Honghu Zhu, PhD, Yan-rong Liu, MD, Ya-zhe Wang, Hong-Xia Shi, Yue-yun Lai, Lan-Ping Xu, MD, Daihong Liu, Xiaojun Huang
Journal: Blood
Blood (2012) 120 (21): 3853.
https://doi.org/10.1182/blood.V120.21.3853.3853
Published: 2012